Corvus Pharmaceuticals, Inc. (CRVS) Financials

CRVS Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 45.6 million 6.9 million
2023-09-30 51.9 million 7.7 million
2023-06-30 58.0 million 8.6 million
2023-03-31 58.2 million 9.3 million

CRVS Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -5.2 million 572000
2023-09-30 -5.4 million 546000
2023-06-30 -5.2 million 537000
2023-03-31 -8.1 million 492000

CRVS Net Income

No data available :(

CRVS Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 - - 1.4 million
2023-09-30 32.2 million - 1.7 million
2023-06-30 37.0 million - 2.0 million
2023-03-31 34.5 million - 2.3 million

CRVS Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 49.0 million
2023-09-30 49.0 million
2023-06-30 47.5 million
2023-03-31 46.6 million

CRVS Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 - 4.0 million 1.7 million -
2023-09-30 - 4.0 million 1.6 million -
2023-06-30 - 4.0 million 1.7 million -
2023-03-31 34000 4.6 million 2.0 million -

CRVS Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 - -
2023-09-30 - 30000
2023-06-30 - 36000
2023-03-31 - 57000

CRVS

Price: $1.68

52 week price:
1.05
4.19

Earnings Per Share: -0.56 USD

P/E Ratio: -3.23

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Volume: 47000

Ebitda: -12.7 million

Market Capitalization: 82.4 million

Links: